Clinical trial
A Prospective, Multicenter，Phase II Clinical Study of Trastuzumab and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
NCT05560308 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter，Phase II Clinical Study of Trastuzumab and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- September 30, 2022
- Completion date
- August 23, 2025
- Enrollment
- 50 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
her2+ advanced breast cancer patients progressing on tki therapy